Healthcare / Medical Care FacilitiesNYSE American
$1.45
-0.01 (-0.68%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-4.5M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
N/A
•EV/EBITDA
7.1x
↓ROE
-6.5%
↓Gross Margin
18.0%
↓Debt/Equity
0.94
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-16.2%
FCF / Net income
2.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $28.1M · net income $-1.6M · FCF $-4.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $28.1M | $28.1M | $28.3M | $21.3M | $19.7M | $17.6M | $17.8M | $20.6M | $19.7M | $19.6M | $18.7M | — | — | — | — | — | — | — |
| Net Income | $-1.6M | $-1.6M | $2.2M | $610000.00 | $1.3M | $194000.00 | $-7.1M | $659000.00 | $1.0M | $1.9M | $930000.00 | $-1.5M | $-952000.00 | $-312000.00 | $38000.00 | $506000.00 | $57000.00 | $-188000.00 |
| EBITDA | $4.1M | $4.1M | $8.9M | $7.0M | $8.1M | $6.3M | $-2.5M | $9.0M | $8.7M | $9.1M | $9.6M | $8.2M | $6.3M | $7.5M | $6.8M | $7.9M | $6.9M | $7.1M |
| EPS | -0.23 | -0.23 | 0.33 | 0.10 | 0.21 | 0.03 | -1.14 | 0.11 | 0.17 | 0.33 | 0.17 | -0.28 | -0.19 | -0.07 | 0.01 | 0.11 | 0.01 | -0.04 |
| Gross Margin | 18.0% | 18.0% | 32.4% | 43.8% | 42.4% | 38.2% | 25.0% | 33.6% | 38.0% | 44.3% | 47.0% | — | — | — | — | — | — | — |
| Operating Margin | -7.2% | -7.2% | 6.3% | 10.9% | 16.4% | 7.7% | -53.1% | 7.5% | 9.4% | 12.3% | 17.6% | — | — | — | — | — | — | — |
| Net Margin | -5.5% | -5.5% | 7.7% | 2.9% | 6.7% | 1.1% | -39.6% | 3.2% | 5.2% | 9.8% | 5.0% | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.94 | 0.94 | 0.92 | 0.78 | 0.66 | 0.72 | 0.18 | 0.08 | 0.13 | 0.15 | 0.24 | 0.48 | 0.50 | 0.79 | 0.89 | 0.76 | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-4.5M | $-4.5M | $-7.8M | $-555000.00 | $6.8M | $4.6M | $9.3M | $7.1M | $6.5M | $7.0M | $7.3M | $7.6M | — | $6.4M | $235000.00 | $1.2M | $6.9M | $6.6M |
| Returns | ||||||||||||||||||
| ROE | -6.5% | -6.5% | 8.7% | 2.7% | 6.1% | 1.0% | -36.6% | 2.5% | 4.1% | 8.1% | 4.3% | -7.6% | -4.4% | -1.6% | 0.2% | 2.5% | 0.3% | — |
| Valuation | ||||||||||||||||||
| P/E | — | — | 9.39 | 25.40 | 13.90 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 7.07 | 7.07 | 3.70 | 2.90 | 2.51 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.40 | 0.40 | 0.83 | 0.72 | 0.85 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -0.9% | -0.9% | 32.9% | 8.0% | — | -1.2% | -13.4% | 4.5% | 0.8% | 4.6% | — | — | — | — | — | — | — | — |
| EPS Growth | -169.7% | -169.7% | 230.0% | -52.4% | — | 102.6% | -1136.4% | -35.3% | -48.5% | 94.1% | 160.7% | -47.4% | -171.4% | -800.0% | -90.9% | 1000.0% | 125.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-39.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.33 → -0.23
Residual
-39.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.